Morphic partners with investor AbbVie on integrin inhibitor development
The Waltham, Massachusetts-based company will receive $100 million, in addition to potential undisclosed milestones and royalties.
Morphic raises $80M in Series B round to fund oral integrin inhibitor development
The company hopes to start IND-enabling studies and clinical trials next year of orally available drugs in a class currently dominated by injected monoclonal antibodies.
presented by
The Top 5 Home Care Franchise Opportunities in the U.S.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.